Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 3.37% vs 175.71% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is -52.36% vs -4.01% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 143.64% vs 23.01% in Mar 2025
Profit After Tax
YoY Growth in year ended Mar 2026 is -70.63% vs -195.98% in Mar 2025
Compare Profit and Loss Results of Oxygenta Pharma
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
112.00
38.00
74.00
194.74%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
112.00
38.00
74.00
194.74%
Expenditure (Ex Depriciation)
Stock Adjustments
-8.00
-1.00
-7.00
-700.00%
Raw Materials Consumed
110.00
16.00
94.00
587.50%
Power & Fuel Cost
6.00
0.00
6.00
0%
Employee Cost
7.00
2.00
5.00
250.00%
Operating Expenses
8.00
0.00
8.00
0%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
0.00
0.00
0%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
0.00
0.00
0%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
128.00
19.00
109.00
573.68%
Operating Profit (PBDIT) excl Other Income
-15.00
18.00
-33.00
-183.33%
Other Income
0.00
0.00
0.00
0%
Operating Profit (PBDIT)
-15.00
18.00
-33.00
-183.33%
Interest
4.00
1.00
3.00
300.00%
Profit before Depriciation and Tax
-19.00
16.00
-35.00
-218.75%
Depreciation
2.00
0.00
2.00
0%
Profit Before Taxation & Exceptional Items
-22.00
15.00
-37.00
-246.67%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-22.00
15.00
-37.00
-246.67%
Provision for Tax
-4.00
4.00
-8.00
-200.00%
Profit After Tax
-17.00
11.00
-28.00
-254.55%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
-74.00
5.00
-79.00
-1,580.00%
Profit Available for appropriations
-91.00
17.00
-108.00
-635.29%
Appropriations
-91.00
17.00
-108.00
-635.29%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-4.75
12.71
-17.46
-137.37%
Profit And Loss - Net Sales
Net Sales 112.98 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 3.37% vs 175.71% in Mar 2025
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) -15.37 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -52.36% vs -4.01% in Mar 2025
Profit And Loss - Interest
Interest 4.78 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 143.64% vs 23.01% in Mar 2025
Profit And Loss - Profit After Tax
Profit After Tax -17.57 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -70.63% vs -195.98% in Mar 2025